$BCLI above upper bollie $3.74 Nasdaq CM Websi
Post# of 63699
(Total Views: 136)
Posted On: 02/21/2017 12:58:18 PM
$BCLI above upper bollie $3.74
Nasdaq CM
Website
10-Q 11/14/17
80% x 96% Strong buy
Ultra low float
Shares Outstanding 18.69M
Float 16.23M
% Held by Insiders 15.19%
% Held by Institutions 9.70%
Shares Short 568.34k
Short Ratio 7.59
Short % of Float 3.50%
Shares Short (prior month) 3555.38k
Last ten trades
Stock technical analysis
News
and filings
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The companys NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.
Nasdaq CM
Website
10-Q 11/14/17
80% x 96% Strong buy
Ultra low float
Shares Outstanding 18.69M
Float 16.23M
% Held by Insiders 15.19%
% Held by Institutions 9.70%
Shares Short 568.34k
Short Ratio 7.59
Short % of Float 3.50%
Shares Short (prior month) 3555.38k
Last ten trades
Stock technical analysis
News
and filings
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The companys NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.
(0)
(0)Scroll down for more posts ▼